New Hepatitis C Treatment Option Available for Patients Who Failed DAA Therapy

In a new study published in the New England Journal of Medicine, lead investigator Marc Bourliere, MD, from the Hospital Saint Joseph in Marseilles, and his colleagues conducted 2 phase 3 clinical trials to explore treatment options for those chronically infected with hepatitis C (HCV) who have had no success with DAA therapy. Dr. Bourliere et al’s first trial, POLARIS-1, involved 300 patients with HCV genotype 1 who had previously received a drug combi

The Week in Review: May 19 – June 2, 2017

Friday, June 2, 2017 News Recap Boomers Should Be Tested Most of the HepC-related news last week from various agencies in the USA stressed the fact that Baby Boomers should be tested and that hepatitis C is a hidden and growing danger (GET TESTED: 1 in 30 baby boomers have Hepatitis C, 70 percent are unaware). In Canada voices of dissent can be heard regarding the federal government’s asinine decision NOT to test Boomers.  The decision was based ...

New Combo Pill Offers Hope to Hepatitis C Patients Who Fail Other Treatment

3-drug mixture was nearly 100 percent effective in drug company trials WEDNESDAY, May 31, 2017 (HealthDay News) -- A pill that contains three powerful antiviral drugs might offer a cure for many hepatitis C patients who have failed other treatments, researchers report. The pill -- which contains the antiviral drugs sofosbuvir (Sovaldi), velpatasvir and voxilaprevir -- was nearly 100 percent effective in curing hepatitis C in patients whose disease retu...

DAA Combination Treatment Fast and Effective for Hepatitis C

Sofosbuvir, velpatasvir, and voxilaprevir for 8 weeks does the trick across all genotypes, treatment experienced, DAA relapse or cirrhosis! Two phase 2 studies of combination direct-acting antiviral agent (DAA) treatments were published recently in Gastroenterology. They were accompanied by an editorial simply titled “Hepatitis C Therapy: Game Over!” The optimism of that title stems from the strength of the results the two studies produced and the vari

Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients

If Approved, SOF/VEL/VOX Would Be the First Once-Daily Single Tablet Regimen Available for Salvage for Patients Who Have Failed Prior HCV Therapy with Oral Direct-Acting Antiviral Agent Regimens.  U.S. NDA Planned for Q4 2016 FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 20, 2016-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced topline results from four international Phase 3 clinical studies (POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4) evaluating an